Ahmed Lasfar
Overview
Explore the profile of Ahmed Lasfar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jhawar S, Wang S, Thandoni A, Bommareddy P, Newman J, Marzo A, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37433716
Background: Immunotherapies are becoming front-line treatments for many advanced cancers, and combinations of two or more therapies are beginning to be investigated. Based on their individual antitumor capabilities, we sought...
2.
Thepmankorn P, Bach J, Lasfar A, Zhao X, Souayah S, Chong Z, et al.
Cytokine
. 2020 Dec;
138:155404.
PMID: 33360025
The new coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can trigger a hyperinflammatory state characterized by elevated cytokine levels known as hypercytokinemia or cytokine...
3.
Newman J, Chesson C, Herzog N, Bommareddy P, Aspromonte S, Pepe R, et al.
Proc Natl Acad Sci U S A
. 2020 Jan;
117(2):1119-1128.
PMID: 31888983
Reprogramming the tumor microenvironment to increase immune-mediated responses is currently of intense interest. Patients with immune-infiltrated "hot" tumors demonstrate higher treatment response rates and improved survival. However, only the minority...
4.
Lasfar A, Balan M, Cohen-Solal K, Zloza A
Front Oncol
. 2019 Dec;
9:1131.
PMID: 31799174
No abstract available.
5.
Lasfar A, Zloza A, Silk A, Lee L, Cohen-Solal K
J Interferon Cytokine Res
. 2018 Jul;
39(1):22-29.
PMID: 30020822
Interferon (IFN)-λ, a type III interferon (IFN), is a member of a new family of pleotropic cytokines that share high similarity with classical IFNs α and β (IFN-α/β), type I...
6.
Cohen-Solal K, Kaufman H, Lasfar A
Pigment Cell Melanoma Res
. 2017 Nov;
31(2):241-252.
PMID: 29090514
Resistance to targeted therapy in cancer is often coupled with the acquisition of a pro-invasive phenotype by tumors cells and a highly permissive tumor microenvironment promoting drug resistance. Transcription factors...
7.
Lasfar A, Zloza A, de la Torre A, Cohen-Solal K
Front Immunol
. 2016 Dec;
7:598.
PMID: 28018361
IFN-λ is the newly established type III IFN with unique immunomodulatory functions. In contrast to the IFN-α/β family and to some extent IFN-γ, IFN-λ is apparently acting in specific areas...
8.
Kohlhapp F, Huelsmann E, Lacek A, Schenkel J, Lusciks J, Broucek J, et al.
Cell Rep
. 2016 Oct;
17(4):957-965.
PMID: 27760326
In light of increased cancer prevalence and cancer-specific deaths in patients with infections, we investigated whether infections alter anti-tumor immune responses. We report that acute influenza infection of the lung...
9.
Lasfar A, Gogas H, Zloza A, Kaufman H, Kirkwood J
Immunotherapy
. 2016 Jul;
8(8):877-88.
PMID: 27381684
Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this...
10.
Lasfar A, de laTorre A, Abushahba W, Cohen-Solal K, Castaneda I, Yuan Y, et al.
Oncotarget
. 2016 Jul;
7(31):49259-49267.
PMID: 27363032
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and...